initiator and sustainer in combination with JAK2V617F.
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INTRODUCTION
Myeloproliferative neoplasms (MPNs) are clinically characterized by the chronic overproduction of differentiated peripheral blood cells and a gradual expansion of malignant intra-/extramedullary hematopoiesis. Mutations in Janus kinase 2 (JAK2) [1] [2] [3] [4] , myeloproliferative leukemia protein (MPL) 5 , and the recently reported calreticulin (CALR) 6,7 are considered to play a "driver" role in MPNs. JAK2 mutations (e.g.
JAK2V617F
and JAK2 exon 12 mutations) are the most frequent of these; almost all polycythemia vera (PV) patients and about half of essential thrombocythemia (ET) and primary myelofibrosis (PMF) patients have these mutations. [1] [2] [3] [4] 8, 9 JAK2V617F mutations induce the phosphorylation of JAKs and STATs in cytokine-dependent cell lines without cytokine stimulation and contribute to autonomous cell growth 1, 4 . JAK2V617F leads to
MPNs in all transgenic [10] [11] [12] or knock-in mouse 13-16 models, and is thought to play a central role in MPN development.
In addition to the above driver mutations, mutations in epigenetic regulators such as TET2, DNMT3A, ASXL1, EZH2, and IDH1/2, have been reported. 17 Of these, TET2, a methylcytosine dioxygenase that converts 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5-hmC), [18] [19] [20] is mutated in chronic-phase MPNs, specifically in 10-17% of PV, 4-11% of ET, and 8-25% of PMF. [21] [22] [23] TET2 is also mutated in Exome sequencing of DNA from many MPN patients revealed that the median number of mutations per patient was 6.5 in PV, 6.5 in ET, and 13.0 in PMF. 6 Despite this mutation analysis study in MPN patients and the above-mentioned mouse studies, it still seems unclear whether a single gene mutation is sufficient for the initiation of human MPNs. To identify the mechanism underlying the initiation and development of MPNs, we focused on JAK2V617F and loss-of-TET2, the former as a representative of driver gene mutations and the latter as a representative of mutations in epigenetic regulators, and examined the influence of single or double mutations on stem/progenitor behavior, clonal evolution, and disease phenotype in MPNs.
METHODS

Mice
JAK2V617F transgenic mice (JAK2V617F-TG) 12 and TET2 heterozygous knock-down (TET2 trap/+ ) mice 31 were previously generated and reported. They were backcrossed at least eight times onto C57BL/6 mice (B6-CD45.2). The TET2 trap/trap mice frequently died during the neonatal period on the B6-CD45.2 background; therefore we used their fetal liver (FL) cells (FLs) for the transplantation assays. B6 mice congenic for the CD45.1 locus (B6-CD45.1) were purchased from Sankyo Lab Service.
We crossed male JAK2V617F-TET2 trap/+ mice with female TET2 trap/+ mice, and obtained the following four types of E14.5 fetuses for the transplantation assays:
JAK2WT-TET2WT (WT), JAK2WT-TET2 trap/trap (TET2KD), JAK2V617F-TET2WT
(JAK2V617F), and JAK2V617F-TET2 trap/trap (double mutant). Animal studies were performed in accordance with the local University of Miyazaki Ethics Committee.
Transplantation assays
We intravenously transplanted 1x10 6 of each of the E14.5 FL cell types (B6-CD45.2) into lethally irradiated 8-week-old B6-CD45.1 mice. Transplanted recipients were sequentially analyzed in terms of complete blood cell counts, cell surface markers and 
FACS analysis
FACS analysis was performed using a MACSQuant Analyzer (Miltenyi Biotec) as previously described. 
Colony replating assay
Fifty thousand whole BM cells were plated in methylcellulose (StemCell Technologies Inc.) according to the manufacturer's instructions. After culture for one week, colonies were counted, and single-cell suspensions (5x10 4 cells) of colonies were subsequently replated under identical conditions. Every one week, replating was repeated in the same 
Histological examination
Tissue samples were fixed in formalin, paraffin-embedded, and sectioned for hematoxylin-eosin staining or Gomori silver staining according to standard protocols.
Megakaryocytes in BM at 6-8 weeks post-transplantation were quantitatively assessed in size by measuring the diameter of the cytoplasm. For immunohistological evaluation, after autoclave pretreatment, tissue samples were stained by Ki-67 primary antibody (Abcam) and biotinylated secondary antibody. Standard Ultra-Sensitive ABC Peroxidase Staining kit (Pierce) and 3, 3'-diaminobenzidine (Vector Laboratories) were used for detection and visualization.
DNA damage, cell cycle, and apoptotic status of LSKs
Mice were given bromodeoxyuridine (BrdU)-containing water (1 mg/ml) for seven days.
BM cells were analyzed using the Apoptosis, DNA damage and Cell Proliferation kit (BD Biosciences). CD45.2-LSKs were gated and the proportion of DNA damaged, cycling, and apoptotic cells were assessed by phosphorylated histone H2AX (γ H2AX), BrdU, and cleaved poly (ADP-ribose) polymerase (PARP) positivity, respectively. 
Microarray
RNA was isolated from 2-6 x 10 4 BM-LSKs obtained from recipients of the four types of FLs. The samples were amplified using the Ovation Pico WTA System V2 (NuGen).
Two micrograms of purified, amplified cDNA were labeled with Cyanine 3 using the Genomic DNA Enzymatic Labeling Kit and then hybridized on a Mouse GE 8x60K
array, and the data were analyzed with GeneSpring (Agilent). Gene set enrichment analysis (GSEA) was performed across the complete list of genes ranked by signal-to-noise ratio according to their differential expression. 33 All data are MIAME-compliant, and the raw data were deposited at Gene Expression Omnibus (accession number GSE62302).
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RESULTS
Loss-of-TET2 worsens JAK2V617F-induced MPNs
To compare the phenotypes of the single mutation JAK2V617F-induced MPNs and double mutation JAK2V617F and TET2KD-induced MPNs, considering the neonatal death of TET2KD mice and a necessity to exclude the influence of mutations in BM niche cells, we performed non-competitive transplantation assays. We transplanted four types of E14.5 FL cells (FLs), namely WT, TET2KD, JAK2V617F, and double mutant, into lethally irradiated recipients. The fraction of LSKs in TET2KD-FLs and in double mutant-FLs increased compared with that in WT-FLs, but the proportion of long-term HSCs (CD150 + LSKs) was comparable among the four types of E14.5 FLs ( Figure S1 ).
Compared to the recipients transplanted with WT cells, the recipients of TET2KD cells at 20-28 weeks after transplantation showed normal blood cell count, no splenomegaly, comparable overall survival duration, and minimal extramedullary hematopoiesis of the lung and liver, indicating that TET2KD cells developed a subtle clinical phenotype similar to CMML-like MPNs (Figure 1) . However, the recipients of JAK2V617F cells at 20-28 weeks after transplantation showed leukocytosis, anemia, thrombocytosis, splenomegaly, shorter survival duration, moderate extramedullary
For personal use only. on April 15, 2017. by guest www.bloodjournal.org From hematopoiesis, and fibrosis in BM and spleen, indicating that JAK2V617F cells induced clinically PMF-like MPNs. Consistent with this, megakaryocytes from recipients of JAK2V617F cells formed dense clusters, and were significantly larger than those from recipients of WT cells. They also showed an abnormal nuclear-cytoplasmic ratio, hyperlobular nuclei, and emperipolesis. Furthermore, double mutant cells showed not only the phenotype of JAK2V617F cell recipients, but also prolonged leukocytosis, splenomegaly, and severe extramedullary hematopoiesis with modestly shorter overall survival. Megakaryocytes in recipients of double mutant cells were smaller than those in recipients of JAK2V617F cells (but still larger than those in recipients of WT cells), and showed additional atypical nuclear features such as hypolobulation. These results indicated that the combination of loss-of-TET2 and JAK2V617F worsened the disease compared to single JAK2V617F-induced MPNs.
Most myeloid cells with both JAK2V617F and loss-of-TET2 mutations are in the proliferative phase
Since the phenotype of recipients of double mutant cells was more unfavorable than that of JAK2V617F cell recipients, we evaluated the proliferative activity of myeloid lineage cells from all four recipient groups at 20-28 weeks after transplantation. The proportion weeks after transplantation ( Figure 1D ), with a decreased number of nucleated cells in both the femur and spleen. We performed the same types of experiments in recipients at 6-8 weeks after transplantation, and found that at this time point BM fibrosis did not occur (data not shown).
In contrast, at 6-8 weeks after transplantation, recipients of JAK2V617F cells 
Loss-of-Tet2 interferes with cell cycle progression in JAK2V617F-LSKs and restores their HSC signature
To examine the mechanism responsible for both the decreased HSC self-renewal capacity caused by JAK2V617F and for the compensation in this decrease by the addition of loss-of-TET2, we assessed DNA damage, cell-cycle status, and apoptosis in LSKs from the 2 nd recipients of the four types of cells at 16 weeks after transplantation ( Figure 6A ). We did not observe an increment of γH2AX positivity in JAK2V617F-LSKs, and there was no difference in degree of γH2AX positivity among the four types of LSKs. The proportion of actively cycling JAK2V617F-LSKs was greater than in WT-LSKs, and this was lowered to levels comparable to WT-LSKs by loss-of-TET2 ( Figure 6A ).
Next we performed gene expression analysis using BM-LSKs from recipients of the four types of FLs. There were close similarities in the whole-genome expression profiles between JAK2V617F-LSKs and double mutant-LSKs ( Figure 6B ). Consistent (Table S1 ).
DISCUSSION
In this study we used JAK2V617F transgenic and TET2 knock-down mouse models. JAK2V617F mutation has frequently been observed in MPNs, and is sufficient that TET2 mutation occurred before JAK2V617F in some MPN patients who had both mutations, but the order was the opposite in other cases. 50 In the first case, loss of TET2 might play a role in evolving clonal hematopoiesis, which is essential for MPN initiation, and in the second case might accelerate the degree of malignancy of already-developed MPNs. We also note the effect of TET2 mutation on MPN prognosis. 
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